Orciprenaline

In the long-term control of chronic airway diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD), bronchodilators are one of the core treatment categories. As a selective β₂ adrenoceptor agonist, orciprenaline is a classic drug in this field. Its mechanism of action is to relax bronchial smooth muscle by activating the β₂ receptors on airway smooth muscle, and meanwhile inhibit the release of allergic mediators from mast cells to relieve airway spasm. Clinically, it is mainly used for the treatment of bronchial asthma, asthmatic bronchitis, and COPD accompanied by bronchospasm, and has clear application value for patients who cannot tolerate the adverse reactions of non-selective agonists such as ephedrine and isoprenaline.

The global market size of β₂ receptor agonists, to which orciprenaline belongs, is approximately USD 9.2 billion, with inhalation formulations accounting for more than 65% and a compound annual growth rate maintained at around 3.7%. In the domestic market, this variety is currently in the application expansion stage, and there is no publicly verifiable segmented market size data; the competition landscape is dominated by overseas original research products, domestic generic drugs are still in the initial stage, and clinical applications are mostly concentrated in the respiratory department of secondary and lower medical institutions.

The original research enterprise of orciprenaline is Boehringer Ingelheim, with the original research trade name Alupent (metaproterenol). The core compound patent expired globally in 1980. The main dosage forms of the original research product include inhalation aerosol (0.65mg per actuation), oral tablets (10mg, 20mg) and injections. The original research inhalation aerosol has been included in the FDA Reference Listed Drug Catalog, and the original research preparation has not been imported into China yet. As of the retrieval time point, there is no approved orciprenaline preparation product marketed in China, and the CDE API registration platform has not yet included the valid API registration number of this variety. (Data as of April 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of orciprenaline impurity reference standards. Most of the products are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the experimental needs in different stages such as API research and development, quality research, and registration declaration.